Protara Therapeutics found using ticker (TARA) now have 4 analysts covering the stock with the consensus suggesting a rating of ‘Strong_Buy’. The range between the high target price and low target price is between 50 and 37 and has a mean target at 45. Now with the previous closing price of 20.7 this is indicating there is a potential upside of 117.4%. The 50 day MA is 20.22 and the 200 moving average now moves to 20.96. The market cap for the company is $202m. You can visit the company’s website by visiting: http://www.protaratx.com
Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics and changed its name to Protara Therapeutics in May 2020. Protara Therapeutics is based in New York, New York.